PuSH - Publication Server of Helmholtz Zentrum München: Targeting VEGF-A in an immunocompetent orthotopic mouse model of mesenchymal glioblastoma improves antitumorigenicity and decreases proinflammatory response in normal brain tissue after fractionated radiotherapy.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Nieto, A.E.* ; Fleischmann, D.F.* ; Unger, K. ; Albrecht, V.* ; Maas, J.* ; Zitzelsberger, H. ; Belka, C. ; Proescholdt, M.* ; Lauber, K. ; Niyazi, M.* ; Orth, M.*

Targeting VEGF-A in an immunocompetent orthotopic mouse model of mesenchymal glioblastoma improves antitumorigenicity and decreases proinflammatory response in normal brain tissue after fractionated radiotherapy.

Adv. Therap. 8:2400374 (2025)

Publ. Version/Full Text

Research data

DOI

	Open Access Gold (Paid Option)

Abstract
Metrics
Extra information

Glioblastoma is the most aggressive primary brain tumor characterized by a dismal prognosis and a profound therapy resistance that is most evident for the mesenchymal molecular subtype of glioblastoma. Targeting vascular endothelial growth factor (VEGF)-A by the monoclonal antibody bevacizumab, despite failing to improve survival in randomized trials, yields relevant benefits in glioblastoma patients such as reduction of radionecrosis, an adverse event associated with radiotherapy. This demands for continued research to identify optimal combinations of anti-VEGF-A and standard therapies for glioblastoma treatment. We show here that blocking VEGF-A in an immune competent orthotopic glioblastoma mouse model resembling the adverse mesenchymal molecular subtype increases the tumoricidal effect of computed tomography (CT)-based fractionated radiotherapy and also rectifies irradiation-induced expression of genes with known association to mesenchymal subtype enrichment as revealed by microarray-based transcriptome analyses of explanted tumors. VEGF-A blockade also decreases the expression of myeloid-cell-related gene patterns in irradiated tumors and lowers inflammatory response in normal brain tissue after tumor irradiation. Hence, these data both provide a hint how blockade of VEGF-A increases the effect of radiotherapy in mesenchymal glioblastoma and a mechanistic base for clinical observations reporting reduced incidences of radionecrosis in glioblastoma patients treated with radiotherapy upon concurrent administration of bevacizumab.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Glioblastoma ; Inflammation ; Mesenchymal ; Normal Brain Tissue ; Radiotherapy ; Vegf-a; Phase-ii Trial; Radiation Necrosis; Recurrent Glioblastoma; Gene-expression; Bevacizumab; Reirradiation; Resistance; Therapy; Immune; Glioma

ISSN (print) / ISBN 2366-3987

e-ISSN 2366-3987

Journal Advanced Therapeutics

Quellenangaben Volume: 8, Issue: 2, Article Number: 2400374

Publisher Wiley

Publishing Place 111 River St, Hoboken 07030-5774, Nj Usa

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Translational Metabolic Oncology (IDC-TMO)

Grants FoeFoLe program of the medical faculty of the "Ludwig-Maximilians-Universitat" (LMU) Munich, Germany
Projekt DEAL